Anteris finds encouraging DurAVR performance in challenging small-annulus patients
Anteris has reported encouraging one-year results for its investigational DurAVR heart valve in 100 patients with severe aortic stenosis and small aortic annuli. The data now set a higher bar for the company’s pivotal randomised PARADIGM trial, which is testing DurAVR against commercial valves.
- 1% heart failure hospitalisation at one year
- 8.9 mmHg mean pressure gradient and 2.2 cm² mean effective orifice area
- No moderate or severe paravalvular leak or valve-related deaths reported
- 96% of patients in NYHA class I/II at one year
- PARADIGM trial continues as the decisive comparative test
Add us as a preferred source on Google
DurAVR posts low hospitalisation rate in small-annulus cohort
Anteris Technologies Global Corp. (ASX:AVR) has reported a 1% heart failure hospitalisation rate at one year for its investigational DurAVR transcatheter heart valve, a notable result in a patient group where elevated gradients and prosthesis-patient mismatch can be persistent concerns. The findings cover 100 patients with severe aortic stenosis and small aortic annuli, an anatomy represented by a mean annulus area of 404 ± 37 mm².
DurAVR maintained a mean pressure gradient of 8.9 mmHg at one year, down from 48.1 mmHg at baseline, while mean effective orifice area increased from 0.8 cm² to 2.2 cm². The company reported no moderate or severe paravalvular leak, no valve-related deaths and no moderate or severe haemodynamic valve deterioration through one year.
Symptoms improved, but the evidence remains pooled
The clinical picture also shifted substantially. The proportion of patients in New York Heart Association class I or II rose from 39% at baseline to 96% at one year, with 81% recording symptom improvement. At 30 days, 97% were free from moderate or severe prosthesis-patient mismatch.
That result came from a symptomatic and clinically complex cohort: 61% of patients were in NYHA class III or IV at baseline, mean STS-PROM was 4.7%, and the group included heavy calcification and 9% bicuspid anatomy. A cardiac magnetic resonance substudy involving 64 patients found left ventricular mass had regressed by 24% at one year, although the company presents that finding as consistent with, rather than definitive proof of, sustained ventricular unloading.
The headline figures need to be read alongside the less favourable event data. All-cause mortality was 6%, comprising two cardiovascular deaths, two deaths from non-cardiac infections, one cancer death and one fatal car accident. Stroke occurred in 3% of patients and 9% required a new permanent pacemaker.
PARADIGM trial carries the comparative burden
The results were pooled from Anteris’ EMBARK and early feasibility studies in the United States and Europe, rather than generated by a randomised comparison with an approved commercial valve. The company itself cautioned that cross-trial comparisons should be treated carefully. The 1% heart failure hospitalisation rate therefore provides a supportive signal, but it does not establish superiority over existing TAVR products.
The next test is the actively enrolling PARADIGM trial, a randomised head-to-head study of approximately 1,000 patients across the United States and Europe. It will compare DurAVR with commercially available TAVR valves on a one-year composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalisation. The trial follows the first US PARADIGM patients, while Anteris has also been expanding clinical and manufacturing activity as the programme advances.
DurAVR remains investigational and is not available for commercial use or sale. The pooled one-year data strengthen the device’s clinical narrative, particularly in the difficult small-annulus population, but the investment case still turns on whether the same performance holds in a larger, randomised population against established valves.
Bottom Line?
The one-year results give Anteris a favourable starting point, but PARADIGM must now show whether the signal survives randomised comparison and broader patient exposure.
Questions in the middle?
- Can PARADIGM reproduce DurAVR’s low heart failure hospitalisation rate in a randomised commercial comparison?
- Will the 9% pacemaker rate and 6% all-cause mortality remain consistent as enrolment expands?
- Can the reported haemodynamic performance translate into regulatory approval and eventual commercial adoption?
Sources
1-
One-Year Data in 100 Patients (opens in a new tab)Verified source. Anteris Technologies Global Corp · 23 Nov 2026